Journal profile · Immunology and Microbiology-Immunology
Clinical and Translational Allergy
ISSN 2045-7022 · BioMed Central · ENGLAND · Continuous publication · Founded 2011
Clinical and Translational Allergy: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 4.22; fully open access; APC about USD 3,690; median 143 days to acceptance (104 articles, last 24 months); acceptance rate 26% (journal website); 136 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Clinical and Translational Allergy is published by BioMed Central and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Food Allergy and Anaphylaxis Research, Allergic Rhinitis and Sensitization and Asthma and respiratory diseases, together about 49.6% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as research letters, editorials, and letters to the editors. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.Open access publishing enables free access to all content ensuring a wide dissemination of articles; the electronic format and expert peer review allows for very rapid publication. Clinical and Translational Allergy is an international journal reaching out far beyond the borders of Europe, and invites clinicians and researchers from all countries of the world to contribute. Keywords allergy, asthma, hypersensitivity Abstracting and Indexing Information CAS: Chemical Abstracts Service (ACS) Directory of Open Access Journals (DOAJ) Embase (Elsevier) Open Access Journal Index – OAJ (NSLC & CEPIEC) PubMed (NLM) Science Citation Index Expanded (Clarivate Analytics) SCOPUS (Elsevier) Web of Science (Clarivate Analytics)
From the journal's Aims & Scope
Research area (LetPub): Immunology and Microbiology-Immunology
Editor-in-chief Oliver PfaarPublisher website
Editorial board by country: 1 in mainland China (about 5%); most named Spain 4, Germany 3, United Kingdom 2, Italy 2, Portugal 2 (20 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Food Allergy and Anaphylaxis ResearchMedicine17.3%
- Allergic Rhinitis and SensitizationMedicine17.1%
- Asthma and respiratory diseasesMedicine15.2%
- Contact Dermatitis and AllergiesMedicine6.8%
- Drug-Induced Adverse ReactionsMedicine5.9%
- Dermatology and Skin DiseasesMedicine4.3%
- Urticaria and Related ConditionsMedicine3.7%
- Respiratory and Cough-Related ResearchMedicine3.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Allergy | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Allergy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Allergy | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceMEDLINEPubMedEmbaseCASPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.22LetPub ·
- Impact factor (publisher)
- 4.2Publisher website ·
- Impact factor (publisher) 2025
- 4.2Publisher website ·
- CiteScore 2026-06
- 6.7LetPub ·
- CiteScore (publisher)
- 6.7Publisher website ·
- CiteScore (publisher) 2025
- 6.7Publisher website ·
- SJR 2026-06
- 1.4LetPub ·
- SNIP 2026-06
- 1.49LetPub ·
- h-index
- 28LetPub ·
- h-index
- 70OpenAlex ·
- i10-index
- 567OpenAlex ·
- 2-year mean citedness
- 3.08OpenAlex ·
- Self-citation rate
- 7.1%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 102LetPub ·
- Articles per year (publisher) 2025
- 111Publisher website ·
- Downloads per year (publisher) 2025
- 299,833Publisher website ·
Articles by year OpenAlex count · 2,339 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 81 | 81 | 30 |
| 2025 | 136 | 136 | 355 |
| 2024 | 102 | 102 | 598 |
| 2023 | 124 | 124 | 1,022 |
| 2022 | 122 | 122 | 1,792 |
| 2021 | 98 | 98 | 1,661 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
143 daysMedian, submission to acceptance · P25–P75 107 days – 176 days
- Acceptance to online
- —
- Submission to online
- —
- Sample
- 104 articles with submission and acceptance dates (190 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 weeksLetPub ·
- Acceptance rate (publisher)
- 26%Publisher website ·
- Acceptance rate (publisher) 2025
- 26%Publisher website ·
- Submission to first decision
- 13 daysPublisher website ·
- Submission to first decision 2025
- 13 daysPublisher website ·
- Submission to acceptance 2025
- 136 daysPublisher website ·
- Acceptance to publication 2025
- 19 daysPublisher website ·
- Submission to publication (journal-reported)
- about 11 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,690 / GBP 2,930 / EUR 3,380 | Yes | CC BY | |
| OpenAlex | USD 3,690 / EUR 3,380 / GBP 2,930 | — | — | |
| LetPub | USD 3,190 / GBP 2,530 / EUR 2,920 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Reference style
- AMA
- Graphical abstract
- Required
- Cover letter
- Required
- Not considered
- single case reports
Article types accepted7, with length limits
- correspondevii. CorrespondeLength not stated
- editorialablishes a link to the article that the Editorial is written for Text: Should be strictly limited to 1,000 words (there will not be any abstracts or supplements…main text ≤ 1,000 words
- hypothesisvi. HypothesisLength not stated
- letterv. LetterLength not stated
- original articleiv. Original ArticleLength not stated
- position paperii. Position PaperLength not stated
- review articleiii. Review ArticleLength not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, Peer review, Preprints
- AI use Disclosing the use of artificial intelligence (AI)
If you or your co-authors have used Artificial Intelligence Generated Content (AIGC) tools such as ChatGPT and others based on large language models (LLMs) to develop any portion of a manuscript, their use must be described transparently and in detail in the Methods section.
Source ↗Publisher website ·- Authorship Authorship
The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest
The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potent…
Source ↗Publisher website ·- Data availability Expects Data Sharing
Data sharing: expects and peer reviews data sharing Model summary
Please review Wiley’s policy here. This journal expects and peer review data sharing.
Source ↗Publisher website ·- Publication ethics Publication Ethics
Publication ethics: COPE member Model summary
This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley'sTop 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found here.
Source ↗Publisher website ·- Peer review Peer Review and Acceptance
Peer review: single-blind Model summary
The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Manuscripts are single-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.
Source ↗Publisher website ·- Preprints
Preprint policy: accepts articles previously published on preprint servers Model summary
This journal accepts articles previously published on preprint servers.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Continuous publication
- Founded
- 2011
- ISSN
- 2045-7022
- Society / sponsor
- European Academy of Allergy and Clinical Immunology
- Latest issue on the website
- Volume 16, Issue 9 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Clinical and Translational Allergy
What CAS zone is Clinical and Translational Allergy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Clinical and Translational Allergy is in Zone 2 of Medicine, and in Zone 3 of the minor category Allergy. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Clinical and Translational Allergy?
The latest impact factor listed by LetPub is 4.22; CiteScore 6.7, h-index 70.
How long does peer review take at Clinical and Translational Allergy?
Based on the dates recorded on 104 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 143 days (interquartile range 107–176 days); authors report an average review time of about 12 weeks; the journal's website gives an acceptance rate of 26% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Clinical and Translational Allergy?
According to the journal's author guidelines: Reference style: AMA; Graphical abstract: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Clinical and Translational Allergy based?
Of the 20 board members whose country the journal's board page names, 1 (about 5%) are in mainland China; the countries named most often are Spain (4), Germany (3) and United Kingdom (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Clinical and Translational Allergy?
According to LetPub and DOAJ records, Clinical and Translational Allergy is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Web of Science, MEDLINE, PubMed, Embase and CAS; that list has not been checked against each database.
Is Clinical and Translational Allergy open access, and what is the APC?
Clinical and Translational Allergy is a fully open-access journal. APC about USD 3,690.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .